Streetbeat News

Stock Prices

NUZE

NuZee has priced a $1.275 million underwritten public offering of 425,000 shares of its common stock at a public offering price of $3.00 per share. This has led to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 3:35 pm

AMZN

Amazon has started delivering prescriptions using drones in College Station, Texas. Eligible Amazon Pharmacy customers can select 'free drone delivery in less than 60 minutes' at checkout. The service includes access to more than 500 medications and One Medical, a primary care service that combines virtual and in-person consultations. The drones fly over traffic, reducing transit time.

Portfolio Pulse from Nabaparna Bhattacharya

October 18, 2023 | 3:34 pm

NEXI

NexImmune, Inc. (NASDAQ:NEXI) has announced a 1-for-25 reverse stock split of the company's common stock, approved by the Board of Directors and stockholders. The reverse stock split will take effect after the close of trading on The Nasdaq Capital Market on October 18, 2023. The move is intended to increase the per share trading price of the company's common stock to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 3:30 pm

NVVE

Nuvve Corporation has announced the pricing of a $1 million underwritten public offering of approximately 7 million shares of common stock at a price of $0.14 per share. This has led to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 3:30 pm

TXN

Texas Instruments (NASDAQ:TXN) has outperformed the market over the past 15 years, producing an average annual return of 15.76%. If an investor had bought $1000 of TXN stock 15 years ago, it would be worth $9,422.60 today.

Portfolio Pulse from Benzinga Insights

October 18, 2023 | 3:30 pm

TT

Trane Technologies (NYSE:TT) has outperformed the market over the past 10 years by 7.35% on an annualized basis, producing an average annual return of 16.8%. If an investor had bought $1000 of TT stock 10 years ago, it would be worth $4,761.07 today.

Portfolio Pulse from Benzinga Insights

October 18, 2023 | 3:30 pm

FBYD

Shares of Falcon's Beyond Global, Inc. resumed trading but were halted again due to a circuit breaker. The stock is now up by 149.6%.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 3:29 pm

WIT

Wipro Limited's Q2 revenue fell short of expectations, reporting $2.71 billion against the consensus of $2.77 billion. EPS also missed the consensus at $0.06. IT Services revenue declined by 2.3% Q/Q. However, the company highlighted growth in large accounts, with 22 accounts above the $100M range. Wipro's Q3 outlook for IT Services business revenue is between $2.617 billion and $2.672 billion.

Portfolio Pulse from Anusuya Lahiri

October 18, 2023 | 3:25 pm

KO

PEP

STZ

TAP

Coca-Cola (KO) has announced a partnership with Pernod Ricard to launch Absolut Vodka & Sprite, a ready-to-drink pre-mixed cocktail, in 2024. This move is part of Coca-Cola's ongoing strategy to expand into the alcoholic beverage sector through partnerships with alcohol manufacturers. The company has previously partnered with Brown Forman, Constellation Brands (STZ), and Molson Coors Beverage Company (TAP). Coca-Cola's share price has fallen 3% over the last year and 14% year-to-date, while its rival PepsiCo (PEP) has seen a 7% decrease over the last year and 11% year-to-date.

Portfolio Pulse from Chris Katje

October 18, 2023 | 3:24 pm

BGNE

BeiGene Ltd's Phase 3 RATIONALE 315 study met its dual primary endpoints, showing promising results for Non-Small Cell Lung Cancer (NSCLC) treatment. The study evaluated neoadjuvant tislelizumab plus platinum-based doublet chemotherapy. The tislelizumab-based regimen showed a significant improvement in pathological complete response and was well tolerated. BeiGene also announced positive results from the Phase 3 RATIONALE 305 trial for patients with advanced gastric or gastroesophageal junction adenocarcinoma. Despite the positive news, BGNE shares are down 2.39% at $167.45.

Portfolio Pulse from Vandana Singh

October 18, 2023 | 3:23 pm